July 31st, 2025
Every cell contains hundreds of mitochondria, vital organelles tightly integrated into many core cellular processes, and responsible for producing adenosine triphosphate, a chemical energy store molecule used to power the cell. Unfortunately mitochondria become dysfunctional with age, and this is thought to be an important contribution to degenerative aging. A variety of means to address this issue exist or are under development, some more direct and ambitious than others.
Cells will readily take up whole mitochondria from the surrounding tissue environment and make use of them. Thus it is possible to introduce large numbers of mitochondria harvested from cell cultures into a tissue in order to largely replace the native mitochondria. Provided that age-related mechanisms of damage and dysfunction that degrade the effectiveness of mitochondrial populations act slowly, then introducing young, functional mitochondria into an old individual should produce a lasting benefit.
This approach of mitochondrial transplantation has been assessed in small studies using mice, and shown to be feasible. The primary challenge facing those who seek to bring this form of therapy to human patients lies in scaling up existing ad-hoc manufacturing protocols developed for animal studies in order to allow the robust, reliable manufacture of very large batches of human mitochondria. That is where most of the efforts of companies such as cellvie and Mitrix Bio have focused, on the infrastructure of producing mitochondria for transplantation. This has been underway for a few years now, and it seems Mitrix Bio is at the point of conducting an initial safety trial in human volunteers, to start later this year.
